EGFR and cancer: To determine whether the EGFR mutations included in the target regions of the ODxTT and AmoyDx panel corresponded to therapeutic mutations, we referred to the Clinical Interpretation of Variants in Cancer (CIViC) and OncoKB databases18,19.